Novo Nordisk (NVO) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of ...

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy used for weight loss since late April in order to ...

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial.

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Septerna (SEPN) for obesity pills — the latest in a series of moves by the Danish drugmaker as it hopes to ...

Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock. "We are ...

COPENHAGEN (Reuters) -Novo Nordisk, the maker of weight-loss drug Wegovy, earlier this month bought a 200-acre site in Denmark's third largest city Odense and will begin preparatory excavation ...

New cutting-edge software developed in Melbourne can help uncover how the most common heart tumour in children forms and ...